The partnership will advance AI drug discovery
Lifespan Vision Ventures has congratulated its portfolio company, Algen Biotechnologies, for its multi-target research collaboration with AstraZeneca to advance AI-powered drug discovery in immunology.
The partnership is set to combine Algen's functional genomics and machine learning platform with AstraZeneca's scientific expertise and global Research and Development capabilities. The companies are collaborating to identify and validate novel therapeutic targets for immune-mediated and inflammatory diseases, enhancing the discovery of next-generation medicines.
Harry Robb, principal at Lifespan Vision Ventures, said, "We are thrilled to see Algen Biotechnologies achieve this important milestone. The team has built a truly differentiated platform that integrates CRISPR-based functional screening with advanced AI analytics to uncover disease-relevant biology at scale."
"This collaboration with AstraZeneca underscores the strength of Algen's technology and its potential to transform drug discovery."
